The landscape of obesity treatment has evolved dramatically with the introduction of advanced medical therapeutics like retatrutide (RETA, LY3437943), tirzepatide (Mounjaro), and semaglutide (Ozempic). Glucagon-like peptide-1 receptor agonists and co-agonists, originally developed to manage type 2 diabetes, have shown remarkable efficacy in promoting weight loss, making them game-changers for obesity management. However, each drug has unique mechanisms, benefits, and potential applications, including emerging roles in cancer prevention. This article compares their mechanisms, clinical efficacy, broader health benefits, safety profiles, regulatory status, and practical considerations to help patients, clinicians, and informed readers understand how they stack up in 2026. Update: Are GLP-1s the first longevity drugs ? (Nature 2025) Credit: GoodRx Health Mechanism of Action Semaglutide : Semaglutide (Ozempic and Wegovy) is a glucagon-like peptide-1 receptor agonist (GLP-1 RA). It mimics ...
This comment has been removed by the author.
ReplyDelete